Phathom Pharmaceuticals, Inc. (PHAT)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 30M 60M 90M Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 682K Q1 '24: 1.9M Q2 '24: 7.3M Q3 '24: 16.4M Q4 '24: 29.7M Q1 '25: 28.5M Q2 '25: 39.5M Q3 '25: 49.5M Q4 '25: 57.6M Q1 '26: 58.3M Q2 '26: 74.3M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Gross Profit Quarterly

0 25M 50M 75M Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 515K Q1 '24: 1.5M Q2 '24: 5.9M Q3 '24: 14M Q4 '24: 25.8M Q1 '25: 24.8M Q2 '25: 34.5M Q3 '25: 43.3M Q4 '25: 49.9M Q1 '26: 46.3M Q2 '26: 59.2M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Income Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '21: -33.1M Q4 '21: -33M Q1 '22: -37.9M Q2 '22: -45.4M Q3 '22: -42.5M Q4 '22: -46.6M Q1 '23: -30.1M Q2 '23: -31.7M Q3 '23: -35.7M Q4 '23: -69.9M Q1 '24: -70M Q2 '24: -77.3M Q3 '24: -70.8M Q4 '24: -59.4M Q1 '25: -78.9M Q2 '25: -59.9M Q3 '25: -15.3M Q4 '25: -5.9M Q1 '26: -15.5M Q2 '26: -4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-105M -70M -35M 0 35M 70M 105M Q3 '21: -36.7M Q4 '21: -35.8M Q1 '22: -40.7M Q2 '22: -50.9M Q3 '22: -51.1M Q4 '22: -55M Q1 '23: -37.8M Q2 '23: -41M Q3 '23: -43.2M Q4 '23: -79.6M Q1 '24: -82.9M Q2 '24: -91.4M Q3 '24: -85.6M Q4 '24: -74.5M Q1 '25: -94.3M Q2 '25: -75.8M Q3 '25: -30M Q4 '25: -21.1M Q1 '26: -30.4M Q2 '26: -17.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

0 6M 12M 18M Q1 '23: 0 Q2 '23: 0 Q3 '23: 0 Q4 '23: 167K Q1 '24: 426K Q2 '24: 1.4M Q3 '24: 2.4M Q4 '24: 3.8M Q1 '25: 3.7M Q2 '25: 5M Q3 '25: 6.2M Q4 '25: 7.6M Q1 '26: 12M Q2 '26: 15.1M Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '21: -29.1M Q4 '21: -41.3M Q1 '22: -44.8M Q2 '22: -25.7M Q3 '22: -35M Q4 '22: -41M Q1 '23: -39.7M Q2 '23: -22.2M Q3 '23: -31.9M Q4 '23: -43.8M Q1 '24: -69M Q2 '24: -70.7M Q3 '24: -63.6M Q4 '24: -63.5M Q1 '25: -84.9M Q2 '25: -62.7M Q3 '25: -14.1M Q4 '25: -5M Q1 '26: -15.6M Q2 '26: -1.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-90M -60M -30M 0 30M 60M 90M Q3 '21: -29.1M Q4 '21: -41.4M Q1 '22: -44.8M Q2 '22: -26.1M Q3 '22: -35.1M Q4 '22: -41.5M Q1 '23: -39.9M Q2 '23: -22.2M Q3 '23: -32.9M Q4 '23: -44.3M Q1 '24: -69.1M Q2 '24: -70.8M Q3 '24: -63.6M Q4 '24: -63.5M Q1 '25: -84.9M Q2 '25: -62.8M Q3 '25: -14.1M Q4 '25: -5.1M Q1 '26: -15.7M Q2 '26: -2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q2 '21: 36.6M Q3 '21: 37.3M Q1 '22: 38M Q2 '22: 38.3M Q3 '22: 38.8M Q1 '23: 42.4M Q2 '23: 48.5M Q3 '23: 56.8M Q1 '24: 58.4M Q2 '24: 58.6M Q3 '24: 64.6M Q1 '25: 72M Q2 '25: 72.5M Q3 '25: 73.4M Q1 '26: 82.1M Q2 '26: 83.7M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q3 '21: -4.52 Q4 '21: -3.89 Q1 '22: -4.00 Q2 '22: -4.33 Q3 '22: -4.67 Q4 '22: -5.05 Q1 '23: -4.87 Q2 '23: -4.38 Q3 '23: -3.82 Q4 '23: -3.94 Q1 '24: -4.47 Q2 '24: -5.19 Q3 '24: -5.75 Q4 '24: -5.30 Q1 '25: -5.19 Q2 '25: -4.68 Q3 '25: -3.77 Q4 '25: -3.04 Q1 '26: -2.10 Q2 '26: -1.26 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.